Abstract
ABSTRACT Background Malignant mixed Mullerian tumours (MMMTs) of the uterus and adnexa represent aggressive gynaecologic malignancies with a high rate of loco-regional and distant failure. There is no consensus in the community about the preferred chemotherapy regimen in this population. We evaluated two different chemotherapy combinations in terms of toxicity and oncologic outcome in patients with advanced MMMTs. Methods Female patients with advanced MMMTs, residual tumor Results Twenty-four patients (pts) of a median age 64 (49-75) years, performance status Conclusion The two treatments appear overlapping in terms of oncologic outcome but present different toxicity profiles which could suggest individualized treatment in terms of toxicity, cost of treatment and hospitalization (arm A) vs outpatient (arm B) treatment. The two regimens warrant further randomized comparison. Disclosure All authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
